Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 14/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | KDM5A | P29375 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507699 | 0.87 | MRGPRX4 (0.83) | MRGPRX4PTGER1RXRARXRBRXRG | |
| SCHEMBL4505947 | 0.86 | MRGPRX4 (0.55) | MRGPRX4PTGER1RXRARXRBRXRG | |
| SCHEMBL22480779 | 0.84 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL4512326 | 0.81 | MRGPRX4 (0.63) | MRGPRX4PTGER1RXRARXRBRXRG | |
| SCHEMBL4505531 | 0.79 | MRGPRX4 (0.67) | MRGPRX4PTGER1NR4A2 | |
| SCHEMBL4510659 | 0.78 | MRGPRX4 (0.65) | MRGPRX4PTGER1RXRARXRBRXRG | |
| SCHEMBL1333232 | 0.76 | HTR2C (0.58) | MRGPRX4PTGER1RXRARXRBRXRG | |
| SCHEMBL4504753 | 0.75 | SMN1; SMN2 (0.49) | MRGPRX4 | |
| SCHEMBL4499409 | 0.74 | MRGPRX4 (0.63) | MRGPRX4 | |
| SCHEMBL29537506 | 0.73 | KDM4E (0.55) | MRGPRX4PTGER1KDM5AKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | MRGPRX4 1550/4885PTGER1 3083/4885RXRA 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.